Gilead Is UBS's Top Biotechnology Pick, Roden Says

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

Sept. 10 (Bloomberg) -- Matthew Roden, senior biotechnology analyst at UBS Securities, talks with Bloomberg Industries senior health-care analyst Andrew Berens and Bloomberg First Word health-care journalist Sasha Damouni about the Hepatitis C marketplace including drug development and potential mergers and acquisitions in the space. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change